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Abstract   28 
Background: Frequent migraine with four or more headache days per month is a common, disabling 29 
neurovascular disease. From a US societal perspective this analysis models the clinical efficacy and 30 
estimates the value-based price (VBP) for erenumab, a fully human monoclonal antibody that inhibits 31 
the calcitonin gene Wrelated peptide receptor.  32 
Methods: A Markov health state transition model was developed to estimate the incremental costs, 33 
quality-adjusted life-years (QALYs) and value-based price range for erenumab in migraine prevention. 34 
dŚĞŵŽĚĞůĐŽŵƉƌŝƐĞƐ “ŽŶƉƌĞǀĞŶƚŝǀĞƚƌĞĂƚŵĞŶƚ ? ? “ŽĨĨƉƌĞǀĞŶƚŝǀĞƚƌĞĂƚŵĞŶƚ ?ĂŶĚ “ĚĞĂƚŚ ?ŚĞĂůƚŚƐƚĂƚĞƐ35 
across a 10-year time horizon. The evaluation compared erenumab to no preventive treatment, in 36 
episodic and chronic migraine patients that have failed at least one preventive therapy. Therapeutic 37 
benefits are based on estimated changes in monthly migraine days (MMD) from erenumab pivotal 38 
clinical trials and a network meta-analysis of migraine studies. Utilities were estimated using previously 39 
published mapping algorithms. A VBP analysis was performed to identify maximum erenumab annual 40 
prices at willingness to pay (WTP) thresholds of $100,000 - $200,000 per QALY. Estimates of VBP under 41 
different scenarios such as choice of different comparators, assumptions around inclusion of placebo 42 
effect, and exclusion of work productivity losses were also generated. 43 
Results: Erenumab resulted in incremental QALYs of 0.185 versus supportive care (SC) and estimated 44 
cost offsets due to reduced MMD of $8,482 over 10 years, with an average duration of treatment of 45 
2.01 years. The estimated VBP at WTP thresholds of $100,000 - $200,000 for erenumab compared to SC 46 
ranged from $14,238 - $23,998. VBP estimates including the placebo effect and excluding work 47 
productivity ranged from $7,445 - $13,809; increasing to $12,151 - $18,589 with onabotulinumtoxinA as 48 
a comparator in chronic migraine. 49 
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Conclusion: Erenumab is predicted to reduce migraine related direct and indirect costs, and increase 50 
QALYs compared to SC. 51 
  52 
 53 
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 86 
INTRODUCTION 87 
Frequent migraine is a highly disabling neurovascular disease characterized by severe, typically 88 
unilateral headache, commonly accompanied by nausea, photophobia, phonophobia, and aura.1 89 
Migraine prevalence is 3 times higher in women than in men2-7 and is most common between the prime 90 
productive working ages of 18 and 59, with the peak prevalence of migraines occurring at around 40 91 
years of age.8-10  92 
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Migraine can be broadly classified as episodic (EM) or chronic migraine (CM) based on the number of 93 
migraine days and headache days per 28 days (defined as monthly migraine days (MMD); monthly 94 
headache days (MHD)). EM is characterized by <15 MHD and accounts for more than 90% of migraine in 95 
the US population. In contrast, CM is defined by A? ? ?MHD, including at least 8 days with migraine and 96 
accounts for approximately 5%  W 8% of migraine.11 Previous studies have indicated that about 90% of 97 
migraine patients are functionally impaired during an attack, 53% are severely impaired and require 98 
bedrest, and subjects have reported being only about half as productive while working with migraine.9, 12  99 
Preventive therapies are recommended by US guidelines for people who experience four or more MMD 100 
who are overusing acute medication, or who have headache-related disability.17 The mainstay of 101 
migraine prevention has been re-purposed anti-epileptic drugs (topiramate and divalproex), 102 
antidepressants (amitriptyline), and beta-blockers (propranolol), but only 13% of eligible patients 103 
reported current use of preventive therapy in published survey data18. In addition to not being 104 
specifically designed to alter the underlying physiology of migraine, existing treatments are associated 105 
with significant side effects, and it is estimated that more than 80% of treated patients discontinue their 106 
preventive medication within 12 months of initiation.19 OnabotulinumtoxinA was approved by the US 107 
Food and Drug Administration (FDA) in 2010 for preventative use, but is restricted to use in CM patients 108 
only. There is no recommended standard of care or published data in patients who try current 109 
prevention and fail either because of tolerability, lack of effectiveness, or both. There is therefore an 110 
unmet need in these migraine patients. This analysis deploys a US societal perspective, since migraine is 111 
atypical in that indirect costs (absenteeism/disability) and presenteeism (being less productive while at 112 
work) account for up to approximately 70% of total costs.20 Each employee with frequent migraine costs 113 
employers thousands of dollars every year, with estimates between $2,400 and $7,000 for women and 114 
$4,000 and $13,000 for men.21, 22 Developing novel treatments for migraine prevention with better 115 
efficacy or tolerability profiles is a priority for improving migraine outcomes. One promising approach 116 
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targets the calcitonin gene-related peptide (CGRP, a sensory neuropeptide implicated in migraine 117 
pathogenesis) pathway. Erenumab is the only fully human monoclonal antibody in development 118 
targeting the CGRP pathway and the only fully human monoclonal antibody in development that targets 119 
the CGRP receptor. Pivotal studies in EM and CM have completed, and the data package is under review 120 
by regulatory agencies at the time of this writing (Feb 2018). The efficacy of erenumab 140 mg was 121 
demonstrated versus placebo in pivotal studies in EM and CM.23, 24 The primary efficacy endpoint in both 122 
pivotal studies was the change from baseline to the end of the double-blind treatment period in the 123 
mean number of MMD. In the EM study, The mean number of migraine days per month at baseline was 124 
8.3 in the overall population; by months 4 through 6, the number of days was reduced by  3.7 in the 125 
140-mg erenumab group, as compared with 1.8 days in the placebo group (P<0.001 for each dose vs. 126 
placebo). Linear mixed-effects regression models predicted a least squares mean change from baseline 127 
versus placebo for the erenumab 140 mg group of -1.85 MMD (95% CI: -2.33, -1.37; p < 0.001) over the 128 
final 12 weeks of the double-blind period.23 In the CM study, the 140 mg reduced monthly migraine days 129 
versus placebo (-6·6 days vs placebo -4·2 days). Least squares mean change from baseline for erenumab 130 
140 mg versus placebo at week 12 was -2.45 MMD (95% CI: -3.51, -1.38; p < 0.001).24In addition 131 
responder rates i.e.: proportion of patients with a 50% or more reduction in migraine days from baseline 132 
to end of double-blind period ranged from 50% in EM for 140 mg (26% for placebo; odds ratio (OR) 2.81 133 
(2.01 to 3.94)) to 41% in CM (23% for placebo,  KZ ? ? ? ? ? ? ? ?ƚŽ ? ? ? ) ). In pre-specified subgroup analysis 134 
in the clinical studies, erenumab demonstrated a numerically greater reduction in MMD compared to 135 
placebo in patients who had previously failed A? ?ƉƌŝŽƌpreventive treatment, than was observed in the 136 
overall trial populations. Erenumab has therefore demonstrated efficacy in patients who have tried and 137 
failed preventive therapies, a population of patients with greater unmet medical need.25 138 
The value of novel health technologies is typically assessed via cost-effectiveness modeling, comparing 139 
the ratio of incremental health outcomes to incremental costs, known as the incremental cost-140 
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effectiveness ratio (ICER). Erenumab is not approved for use, and pricing is not known at the time of this 141 
writing (Feb 2018), so a direct analysis of its cost-effectiveness is not possible. However, it is useful to 142 
consider what level of price is justifiable given the additional benefits of erenumab over current options 143 
and the potential to displace suboptimal therapies. To do this, one can estimate the value based-price 144 
(VBP) based on incremental costs and quality adjusted life years (QALY).26 The VBP is the maximum price 145 
at which the drug would still be considered cost-effective versus a comparator, when using a defined 146 
willingness to pay (WTP) threshold for additional benefits. In the US, WTP thresholds per incremental 147 
QALY that have been commonly used to assess the cost-effectiveness of novel medical interventions are 148 
$100,000 - $200,000.  149 
The objective of this study is to estimate VBP ranges for erenumab 140 mg, administered 150 
subcutaneously every 4 weeks, in migraine patients who have failed at least one prior preventive 151 
treatment, compared to SC, by evaluating the incremental costs and QALYs within a cost-effectiveness 152 
modeling framework.  153 
 154 
METHODS 155 
We built a Markov model, implemented in Microsoft Excel, based on the clinical data from the EM and 156 
CM pivotal studies for the subgroups of patients with prior treatment failures. The model comprises 157 
health states accounting for patients who are  “on preventive treatment ?,  “off preventive treatment ? 158 
and  “dead ? (accruing no costs or health outcomes). In addition to the primary clinical outcome of MMD 159 
frequency, the model predicts the costs and health-related quality of life outcomes associated with 160 
erenumab ĂƐƉƌĞǀĞŶƚŝǀĞƚƌĞĂƚŵĞŶƚŽĨŵŝŐƌĂŝŶĞŝŶƉĂƚŝĞŶƚƐǁŝƚŚA? ?ƉƌŝŽƌĨĂŝůĞĚƚƌĞĂƚŵĞŶƚ ?ĐŽŵƉĂƌĞĚƚŽ161 
supportive care (SC). EM and CM cohorts are modeled independently based on the clinical trial data, but 162 
outcomes are combined based on a split of the overall treated migraine population between EM and 163 
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CM, based on available literature.27 A comparison of erenumab to onabotulinumtoxinA in exclusively CM 164 
patients is presented as scenario analysis. Based on this output, ranges of the VBP of erenumab are 165 
estimated based on commonly used WTP thresholds.  166 
The cycle length of the model is 28 days, consistent with the primary efficacy outcome (MMD ) and the 167 
frequency of administration of erenumab. Cost and QALY outcomes are discounted at an annual rate of 168 
3%, in line with published US recommendations.28 Clinical outcomes (number of migraine days, life 169 
years) are not discounted. The analysis is performed from a US societal perspective, including the direct 170 
medical costs of treating migraine and the indirect costs of missed work days and lost workplace 171 
productivity. This reflects the working age of the migraine population.23, 24 The model evaluates cost 172 
outcomes in 2017 US dollars. 173 
Time Horizon 174 
The time horizon in these analyses spans 10 years. The erenumab studies were reflective of the migraine 175 
prevalent population, with mean age at baseline for the pivotal studies ranging from 40  W 43 years. The 176 
prevalence of migraine after age 60 falls to about 5% and is less than <1% in CM.29 Published guidance 177 
on the design of economic evaluations also state that the time horizon of analyses should be long 178 
enough to capture all relevant differences between treatment strategies compared.28 The model 179 
assumes that the clinical and economic outcomes of erenumab patients are equal to those in the SC arm 180 
after they have discontinued treatment. This means that there are no further differences between arms 181 
once all patients have discontinued, so incremental outcomes are limited to the duration of erenumab 182 
treatment. Based on the disease epidemiology and the erenumab time on treatment predicted by the 183 
model (full details provided in supplementary material section A), a 10-year time horizon is sufficiently 184 
long to capture the lifetime impact of the decision problem. As over 99% of patients discontinue 185 
erenumab by the end of the simulation, further extrapolation of the clinical trial data is not required. 186 
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Patient population 187 
Erenumab studies enrolled subjects that were either naïve to preventive treatment or previously treated 188 
with preventive medication but failed due to lack of efficacy or intolerability. However, it is anticipated 189 
that erenumab and other CGRP and monoclonal antibodies will be restricted for use to patients who 190 
have failed prior preventive therapies. Therefore, the migraine populations considered in the model are 191 
the subgroups of patients who have previously failed A? ?ƉƌŝŽƌpreventive therapy. In the clinical studies, 192 
a patient was considered to have failed a preventive therapy if they were recorded to have discontinued 193 
due to lack or efficacy or intolerability, at any time. In addition, chronic patients are more likely to seek 194 
treatment and therefore in the base case analysis, the migraine population is modelled as 33% EM and 195 
67% CM.27 A scenario analysis is presented in which the migraine types are evenly split (50% EM, 50% 196 
CM).  197 
Intervention and comparators 198 
The intervention evaluated in the model is erenumab 140 mg, self-administered every 28 days by 199 
subcutaneous injection.  200 
In patients for whom currently available preventive treatments can be efficacious and tolerable, use of 201 
these treatments represents maximum value to the patient and the healthcare system. However, there 202 
is currently no defined standard of care for patients with 4 or more MMD who have tried and failed 203 
either topiramate or propranolol, due to the lack of published evidence from clinical trials or 204 
observational studies. Sequencing these treatments with either one or other generics is also not 205 
supported by evidence-based guidelines. Clinicians resort to sequencing simply due to the lack of other 206 
pharmacologic options. Therefore, neither topiramate nor propranolol are appropriate comparators in 207 
patients with 4 or more MMD who have failed prior preventive treatment. This gap in the data may be 208 
addressed by erenumab. Multiple clinical and insurer sources suggest that in clinical practice, erenumab 209 
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will be used after failure of topiramate or propranolol or a similar beta blocker or antihypertensive, 210 
addressing the high unmet need of migraine patients who have experienced a lack of efficacy or 211 
tolerability from prior preventives. 212 
Although these previously failed patients are likely to have failed multiple preventives, the clinical trial 213 
subgroups of patients who had failed at least one prior preventive were used as a proxy in this analysis. 214 
This assumption retains the sample size available in these subgroups, but is also supported by published 215 
analyses which have shown that the number of prior failed therapies does not substantially affect the 216 
absolute MMD reductions of erenumab.  217 
In clinical practice, most of these patients are typically managed with acute treatments only. As such, 218 
the comparator against which erenumab is assessed in patients who have previously received 219 
preventive therapy is SC, in which patients receive only acute treatment for migraine. 220 
OnabotulinumtoxinA is the only migraine preventive exclusively indicated for CM patients and is 221 
commonly used after the failure of prior preventive treatments. To reflect this, a scenario analysis is 222 
presented in which erenumab is compared to onabotulinumtoxinA in an entirely CM population.17 223 
Clinical trials in migraine prevention have typically observed strong placebo effects,30 but the 224 
administration of placebos, such as sham injections, does not represent a plausible treatment option in 225 
clinical practice. Therefore, we do not consider placebo a relevant comparator in the model. There is an 226 
absence of reliable real-world data on the natural history of migraine. In our modelling we examine two 227 
scenarios. In the base case, the placebo effect attributable to enrollment into the clinical studies and the 228 
administration of sham injections are excluded. It is assumed that patients in the SC cohort of the model 229 
remain at the MMD observed during the 4-week pre-randomization period in the clinical studies, prior 230 
to the start of the double-blind phase. This assumption is tested in a scenario where placebo effect is 231 
included. 232 
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 233 
Model structure 234 
The model is comprised of two primary health states:  “on preventive therapy ? and  “off preventive 235 
therapy ? (Figure 1). Patients are at risk of death in each cycle, based on US general population mortality 236 
rates.31 The risks of death are assumed to be unaffected by MMD or treatment, and life expectancy is 237 
identical in both arms of the model.  238 
In each cycle, patients on treatment are at risk of discontinuation (A), after which they withdraw from 239 
treatment and lose the associated treatment effect. In the absence of real world discontinuation data 240 
for erenumab, baseline persistence rates were taken from US claims data, using onabotulinumtoxinA as 241 
the closest analog to a novel preventive. An exponential function was fitted to the proportion of 242 
patients remaining on onabotulinumtoxinA treatment over a follow up period of 52 weeks.32 A 243 
discontinuation rate ratio of erenumab compared to onabotulinumtoxinA was derived from a network 244 
meta-analysis (NMA) of all-cause discontinuation data reported in 9 clinical studies of preventives in CM 245 
(Supplementary material section A). The predicted time on treatment curve for erenumab was used to 246 
ĚƌŝǀĞƚƌĂŶƐŝƚŝŽŶƐďĞƚǁĞĞŶƚŚĞ “ŽŶƉƌĞǀĞŶƚŝǀĞƚƌĞĂƚŵĞŶƚ ?ĂŶĚ “ŽĨĨƉƌĞǀĞŶƚŝǀĞƚƌĞĂƚŵĞŶƚ ?ŚĞĂůƚŚƐƚĂƚĞƐŝŶ247 
each cycle. The approach is described in greater detail in the supplementary material. Discontinued 248 
patients are assumed to remain untreated for the remainder of the simulation. Transitions between all 249 
three model health states were half-cycle corrected.  250 
In each 28-day cycle, the mean MMD is modeled for patients in the living health states (only  “on 251 
treatment ? shown in Figure 1) (B). Patients are distributed based on the mean MMD, across the range 252 
of possible MMD counts (between 0 and 28 migraine days in each cycle), using previously validated 253 
parametric models (C).33, 34 As shown in hypothetical time points c and d, the shape of the distribution 254 
13 
 
of individual patients by MMD changes to account for both the mean MMD and the asymmetric spread 255 
of individual patients.  256 
The parametric models used in the calculation steps in components B and C are described in greater 257 
detail in the supplementary material.  258 
 259 
Figure 1: Model schematic 260 
 261 
MD, migraine days. Patients can transition to an absorbing death state due to all-cause mortality at any point. 262 
A: Time- and treatment-dependent discontinuation rates determine time on preventive therapy, during 263 
which patients experience the MMD reduction attributed to treatment. B: The cohort of patients achieves 264 
the reduction in mean MMD from baseline, based on clinical trial endpoints. C: Parametric distributions 265 
represent the variation of patients around the mean MMD, and allow outcomes linked to the number of 266 
migraine days to be estimated. 267 
Hypothetical time points c and d indicate how the distribution of patients is estimated based on the 268 
mean MMD of the cohort at different time points. 269 
 270 
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Costs 271 
Drug and administration costs 272 
Preventive therapy and acute migraine medication costs are accounted for in the model (Table 1). 273 
Erenumab is currently undergoing regulatory review by the FDA and, as such, is not yet available for 274 
purchase. In the absence of a list price, value-based price ranges are evaluated based on the model. For 275 
the scenario analysis, onabotulinumtoxinA is estimated to cost $5,035 in drug acquisition costs, and 276 
$649 in administration costs per year (CMS Physician Fee Schedule CPT 99212).  277 
 278 
Medical resource use costs 279 
Medical resource use in the model consists of physician office visits (primary care doctor), emergency 280 
room visits, hospitalizations, and specialist neurologist consultations based on published unit costs 281 
(Table 1). Average annual medical resource use is taken from a published 2009 analysis of survey data 282 
from 7,437 migraine patients in the US.35 The mean patient-reported medical resource use over 12 283 
months was divided by the reported annual number of HD to estimate the medical resource cost per 284 
migraine day in the model.35 The resource use per migraine day and the unit costs are combined in the 285 
model to estimate the weighted average costs of medical resource use for each cohort of patients. 286 
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Table 1: Preventive therapy costs, migraine resource use costs and acute medication costs  287 
Medical resource 
Unit cost 
(2017 USD) 
Average use per year* Use per migraine dayゆ 
Physician visits 
(CPT99212) $44.14 
36 0.720 0.0379 
Emergency room visits 
$939.59 32 0.167 0.0088 
Hospitalization (DRG 102 
and 103) $4,298.35 
37 0.075 0.0039 
Specialist consultations 
(CPT 99215) $146.43 
36 0.221 0.0116 
Acute medicationょ Cost per day of use - 
EM (2017 USD) 
Cost per day of use - 
CM (2017 USD) 
Non-migraine-specific  0.99 1.76 
Migraine-specific  4.94 3.99 
Preventive therapy 
Cost per year  
(2017 USD) 
Frequency of 
occurrence or dosing  
Annual cost 
OnabotulinumtoxinA $1,158.0038 12-weekly $5,035 
*Annual use reported in Munakata 2009, migraine patient cohort. 288 
ゆPatients reported an average of 19 headache days over the previous 12 months. 289 
ょEstimation of costs per day of use based on published breakdown of medication types by frequency of use 290 
and 2017 unit costs. Migraine-specific medication comprised of triptans and triptans and ergot derivatives. 291 
Non-migraine-specific medication comprised of acetaminophen, non-steroidal anti-inflammatory drugs 292 
[NSAIDs], barbiturates, opioids, isometheptene compounds and other over-the-counter medication.  293 
 294 
Acute migraine day medication costs 295 
The distribution of the drug classes by usage and the dosages used to treat acute migraine were 296 
obtained from three studies in the literature.39-41 Using acute medication use data collected in the 297 
erenumab clinical studies, the model differentiates between migraine-specific acute medication 298 
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(comprised of triptans and ergot derivatives), and non-migraine-specific acute medication (comprised of 299 
acetaminophen, non-steroidal anti-inflammatory drugs [NSAIDs], barbiturates, opioids, isometheptene 300 
compounds and other over-the-counter medications).39 Weighted average costs per day of use are 301 
shown in Table 1, and the numbers of days of acute medication use by migraine day frequency are 302 
presented in supplementary data.  303 
 304 
Indirect costs of lost work productivity  305 
The substantial ŝŵƉĂĐƚŽŶĂƉĂƚŝĞŶƚ ?ƐĂďŝůŝƚǇƚŽĨƵŶĐƚŝŽŶĂŶĚĂƐƐŽĐŝĂƚĞĚůŽƐƚƉƌŽĚƵĐƚŝǀŝƚǇĂĐĐŽƵŶƚƐĨŽƌƚŚĞ306 
greatest proportion of total costs attributed to migraine.35, 42 The productivity cost of migraine is split 307 
into two types. Absenteeism days are days in which patients are unable to attend work or school due to 308 
their migraine. Presenteeism days are days in which patient productivity at work or school is reduced by 309 
at least 50% (but less than 100%). The number of days of productivity losses in the model are based on 310 
erenumab clinical trial data, and reflect the sex, age and employment status of the clinical trial 311 
populations. The average costs of absenteeism and presenteeism days are calculated assuming the 312 
median hourly gross wage obtained from the US Bureau of Labor Statistics,43 assuming a 8-hour working 313 
day. As the degree of productivity loss on each presenteeism day (i.e. days where productivity is 314 
reduced by at least 50%) is not known,44 the model assumes lost productivity of 50%. The costs per 315 
absenteeism and presenteeism day used in the model are presented in Table 2, and a scenario excluding 316 
productivity costs is presented in Supplementary Materials. 317 
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Table 2: Estimated indirect costs per absenteeism and presenteeism day 318 
Parameter  Value Source 
Median hourly wage $26.00 Bureau of Labor Statistics, Private sector December 2016 
Number of working hours per day 8 Assumption 
Proportion of productivity loss on 
presenteeism days 
50% Assumption 
Estimated cost per absenteeism day $208.00 Calculated  
Estimated cost per presenteeism day $104.00 Calculated  
 319 
The number of absenteeism and presenteeism days are estimated based on patient responses to the 320 
Migraine Disability Assessment questionnaire collected in the erenumab EM and CM pivotal studies.24, 45 321 
Question 1 of the Migraine Disability Assessment questionnaire refers to absenteeism, and question 2 322 
refers to presenteeism.44 Patient responses from both the EM and CM studies were combined to 323 
generate one complete migraine dataset, in which the relationship between MMD and productivity was 324 
analyzed. Zero-inflated Poisson regression models were fitted and used to predict the average number 325 
of absenteeism and presenteeism days for each possible migraine day frequency (0-28 MMD). As an 326 
example, a person experiencing 15 migraine days in a 28-day period is estimated to have 3.94 327 
presenteeism days and 1.40 days absence, at a total lost productivity cost of $702. The predicted values 328 
by migraine day frequency used to estimate absenteeism and presenteeism costs in the model are 329 
presented in supplementary materials (section B).  330 
 331 
Health-related quality of life 332 
Utility values in the model were estimated as a function of MMD. Patient responses to the Migraine 333 
Specific Questionnaire version 2.1, collected in the pivotal EM and CM clinical studies, were mapped to 334 
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the UK tariff set of the EuroQoL 5-dimension 3-level instrument (EQ-5D-3L) using previously published 335 
algorithms for EM and CM.46 Gillard et al (2012) report algorithms for mapping between the Migraine 336 
Specific Questionnaire and EQ-5D-3L generated based on datasets of 5,770 and 338 participants from 10 337 
countries in the International Burden of Migraine Study survey in EM and CM, respectively. Migraine 338 
Specific Questionnaire responses from the erenumab EM and CM pivotal studies were mapped to the 339 
EQ-5D-3L using the respective algorithm, then pooled to generate one complete migraine dataset. A 340 
longitudinal beta regression model was fitted, with mapped EQ-5D-3L as the response variable, 341 
controlling for MMD and key patient characteristics. The regressions were used to generate predicted 342 
EQ-5D-3L values for each frequency of MMD, which are used in the model to estimate the mean utility 343 
of the patient cohort, weighted by the distribution of patients by migraine day frequency in each cycle. 344 
As treatment status (erenumab 140 mg compared to placebo) was significantly predictive of utility, with 345 
higher utility values predicted for erenumab, the predicted values applied in the model are separated 346 
for actively-treated (erenumab, onabotulinumtoxinA) and untreated patients (SC, post-discontinuation). 347 
This approach is consistent to the assumptions made in the previous economic model for 348 
onabotulinumtoxinA,42 which also assumed an additional treatment effect on utility of active treatment 349 
compared to SC. As an example, a person with 15 migraine days in a 28-day period would have an 350 
estimated utility value of 0.589 on erenumab 140 mg and 0.571 whilst untreated. The values applied in 351 
the model are reported in the outcomes table presented in the Supplementary materials (section B).  352 
  353 
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Results 354 
In the base case analysis, patients receiving SC were estimated to experience an average of 1,949 355 
migraine days over 10 years (Table 3). By comparison, erenumab-treated patients were estimated to 356 
experience 1,805 migraine days, meaning a reduction of 144 migraine days. Because of discontinuation, 357 
this reduction is based on a mean duration of erenumab treatment of approximately 2 years. As a result 358 
of the migraine day frequency reductions, erenumab was associated with increased total discounted 359 
QALYs per person of 0.1849 over the 10 year horizon.  360 
The discounted cost associated with the burden of migraine in patients on SC was estimated to be 361 
$129,889 over 10 years. By reducing the number of migraine days, erenumab was expected to reduce 362 
the total migraine day-related cost by $8,482. This does not include the incremental acquisition costs of 363 
erenumab. Disaggregated incremental migraine day-related costs, showing the contribution of the 364 
different cost types, are presented in Table 4.  365 
Based on the clinical effectiveness of erenumab predicted by the model, VBP ranges were estimated. 366 
These prices represent the maximum annual treatment costs at which erenumab would be considered 367 
cost-effective at WTP thresholds ranging from $100,000 - $200,000 per incremental QALY. Calculation of 368 
the VBP incorporates both the cost reduction and the QALY gain associated with erenumab in the 369 
quantification of the potential monetary value of erenumab treatment. The estimated VBP of erenumab 370 
ranged from $14,238 to $23,998 per year.  371 
The sensitivity of the base case analysis to model input parameter values was assessed in a deterministic 372 
sensitivity analysis based on the estimated VBP. The results of this analysis are presented in 373 
supplementary material section C.  374 
 375 
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 376 
Table 3: Base case model results per person by comparison and treatment arm, over 10 years* 377 
Comparison Erenumab SC Incremental 
Mean duration of treatment 
(years)  
2.01 N/a N/a 
Mean migraine days 1,805 1,949 -144 
Mean discounted QALYs 5.1437 4.9588 0.1849 
Mean discounted migraine 
day-related costs** 
$121,407 $129,889 -$8,482 
Societal Value based price***  $14,238 - $23,998 - - 
* Migraine population in the base case model is made up of 33% EM and 67% CM patients27 378 
**Cost estimates do not include the costs of providing preventive medication, as a price of erenumab is not 379 
available  380 
***Maximum acceptable price at a willingness to pay threshold of $100,000  W $200,000 per QALY 381 
 382 
Table 4: Disaggregated incremental costs by comparison and treatment arm, over 10 years 383 
Cost category Erenumab SC Incremental 
Physician visits $2,443 $2,631 -$188 
Emergency room visits $12,061 $12,988 -$927 
Hospitalizations $24,779 $26,684 -$1,904 
Specialist consultations $2,487 $2,679 -$191 
Migraine-specific acute medication $2,599 $2,820 -$221 
Non-migraine-specific acute medication $673 $708 -$36 
Absenteeism $31,339 $32,997 -$1,658 
Presenteeism $45,025 $48,382 -$3,357 
Total $121,407 $129,889 -$8,482 
 384 
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Deterministic sensitivity analysis 385 
To explore the sensitivity of VBP estimates to key input parameter values, deterministic sensitivity 386 
analysis (DSA) was performed, in which upper and lower bounds of individual model parameters were 387 
tested to identify model drivers in each of the comparisons assessed. The results of this analysis were 388 
quantified as the percentage deviation from the base case VBP estimate, calculated based on a WTP 389 
threshold of $150,000 per incremental QALY. The estimate of the VBP was driven mostly by the relative 390 
reduction in migraine days of erenumab, reflecting uncertainty in the NMA outcomes parameterizing 391 
this. There was smaller influence of migraine day-related outcomes, primarily utility estimates, 392 
productivity costs and hospitalization frequency. The maximum variation in the VBP was within +/- 50% 393 
of the base case estimate (Figure 2).  394 
Figure 2: DSA results 395 
 396 
* Relative MMD reduction for erenumab based on NMA endpoints, combined uncertainty for EM and CM 397 
data  398 
**Utility and reference change in MMD are vectors of parameters based on regression models 399 
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 400 
Scenario analyses  401 
In addition to the base case results, four scenarios are presented to test major model assumptions. 402 
The first includes the reduction from baseline in MMD in the placebo cohorts of the clinical studies. 403 
Patients in the SC arm are assumed to achieve this reduction, and patients who discontinue erenumab 404 
are assumed to retain the proportion of the reduction observed in the placebo groups. In this scenario 405 
the VBP ranged from $8,886 to $15,250.  406 
The second scenario also includes the placebo reduction, but also excludes the indirect costs of lost 407 
productivity, considering only costs that would be incurred by a healthcare payer. By combining the 408 
exclusion of these costs with the placebo reduction, this is expected to be the most conservative 409 
scenario with respect to the cost-effectiveness of erenumab. In this scenario, the VBP estimates ranged 410 
from $7,445 to $13,809.  411 
The third scenario assumes that the migraine population is split evenly between EM and CM, assuming 412 
50% EM and 50% CM. Under this assumption, the VBP estimates ranged from $13,331 to $22,553.  413 
The final scenario considers only CM patients, and compares erenumab to onabotulinumtoxinA in 414 
previously treated CM patients. Compared to onabotulinumtoxinA in exclusively CM patients, the VBP 415 
estimates ranged from $12,151 to $18,589. 416 
The ranges of VBP estimated in the base case and scenarios are presented graphically in Figure 3, along 417 
with the assumptions defining each scenario. Full results for each scenario are presented in 418 
supplementary material section C. 419 
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Figure 3 Summary of VBP estimates, assuming a 33% EM, 67% CM split 420 
 421 
WTP, willingness to pay 422 
  423 
 424 
  425 
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Discussion 426 
To achieve efficient allocation of healthcare resources under budget constraints, cost-effectiveness 427 
analysis is increasingly used by healthcare decision makers to prioritize societal preferences for changes 428 
in health status across competing healthcare interventions.28 The MMD reductions and QALY 429 
improvements with erenumab presented here estimate the value of this novel migraine therapy 430 
compared to current practices in migraine patients who have failed prior preventive therapy. In people 431 
with frequent migraine, there are no published data supporting preventive treatment for patients that 432 
have failed at least one prior preventive therapy, therefore this represents an important QALY gain of 433 
approximately 0.184.  434 
At the time of launching a new therapy, there is a necessity to satisfy not only safety and efficacy 435 
requirements, but increasingly the need to highlight economic value in relation to costs to satisfy paying 436 
organizations. Accomplishing this is challenging, considering the full economic value of a new 437 
intervention cannot be fully established before launch, due to the absence of real-word data. Attempts 438 
to estimate economic value of new interventions using only the regulatory data package (i.e. FDA filing) 439 
is limited by this data availability. The analysis described here highlights the challenges of demonstrating 440 
economic value for a new product when no price has been established and real-world evidence is not 441 
available. To circumvent the challenges of conducting an economic value demonstration on a pre-launch 442 
preventive migraine therapy, we have conducted an analysis which seeks to evaluate the annual cost of 443 
treatment that reflects the estimated clinical and economic value of erenumab, using acceptable value 444 
standards (i.e. WTP thresholds). From a US societal perspective, these are the maximum estimated 445 
 ‘ƉƌŝĐĞƐ ?below which erenumab would be cost-effective at a WTP of $100,000 - $200,000 given the 446 
framework of a cost-effective analyses for patients who have failed at least one prior treatment and 447 
against appropriate comparators.  448
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The modeling approach applied in this study is different to that used in previous economic evaluations in 449 
migraine prevention,42, 47, 48 which have adopted decision tree approaches or Markov models based on 450 
health states based on defined ranges of migraine day or headache day frequency. Modeling MMD as a 451 
continuous outcome better captures the outcomes of patients, by accounting for variability in migraine 452 
day frequency without relying on compartmentalizing patients based on response status or arbitrary 453 
categories of MMD, which have been shown to introduce bias into migraine day estimates.49 The 454 
approach allows cost and quality of life outcomes to be linked to individual migraine frequency, rather 455 
than average outcomes for compartmentalized health states. In this way, the model therefore spans the 456 
range of migraine frequency, across EM and CM and is consistent with patient presentation in clinical 457 
practice. This also permits the same model structure to accommodate combined assessments of EM and 458 
CM and for estimating the impact of each individual migraine day event. 459 
Scenarios presented in this paper excluding indirect costs, such as those associated with absenteeism 460 
and presenteeism, lower the VBP range compared to the base case analyses. Consistent with US 461 
guidelines on economic evaluation,28 the analysis here includes missed work days and lost productivity. 462 
In migraine, these costs represent a significant proportion of the economic burden of migraine, and are 463 
often paid by employers due to reduced productivity of people with migraines. We recognize that 464 
healthcare payers may not always consider these costs in assessing the value of novel preventives, 465 
despite their importance to patients and employers and hence VBP were also generated based on this 466 
scenario. Even when the monetary value of QALY gains are ignored, migraine day related costs off-sets 467 
with erenumab (ignoring erenumab drug costs) are still approximately $8,500 over the mean treatment 468 
duration of 2.01 years. These VBP estimates represent one of several factors considered in pricing 469 
decisions, and other factors, such as affordability. Cost-effectiveness models by definition do not factor 470 
in affordability and typically do not address other considerations important to payers, such as the size of 471 
the treated patient population and unmet need.  472 
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The results presented here should be interpreted within the context of the study limitations. This 473 
analysis is based on erenumab treatment practices defined by treatment protocols used in the pivotal 474 
randomized controlled trials in the pre-launch phase of drug development. However, in clinical practice, 475 
physicians and patients may adjust treatment practices to optimize outcomes, and in some cases, 476 
introduce strategies for when to discontinue therapy. It is likely that when erenumab enters treatment 477 
practice, and prior to the establishment of clinical guidelines, clinicians will adjust erenumab use to 478 
meet patient treatment goals. This may include treatment discontinuation in cases of non- or partial- 479 
clinical response. The discontinuation of patients experiencing smaller reductions in MMD will likely 480 
improve estimates of the clinical effectiveness and VBP ranges presented here. In a cohort of treated 481 
subjects, as non-responders or low-responders discontinue, the average MMD reduction of the patients 482 
remaining on treatment will increase, the total number of erenumab-treated patients will reduce, and 483 
thus cost-effectiveness will be more favorable. 484 
The model is also limited by the consideration of MMD as the only metric of disease status, and other 485 
dimensions of migraine, such as duration and severity, are not explicitly considered beyond their 486 
contribution to the definition of a migraine day. Any residual impact during non-migraine day such as 487 
interictal burden, prodromal symptoms, anxiety, and depression is not captured in our analysis, and 488 
should be assessed in the future.50. Improvement in the other dimensions may be indirectly captured by 489 
the application of utility values stratified by treatment (i.e. separate values for patient on 490 
erenumab/onabotulinumtoxinA versus SC), but these are not isolated as separate treatment effects. The 491 
model is also subject to limitations in available data. In particular, there is no evidence of time to 492 
discontinuation for patients treated with erenumab in clinical practice, and the comparative 493 
discontinuation rates applied in the model are derived from available clinical trial data. Furthermore, the 494 
use of cost data from Munakata 2009 is likely to result in an underestimation of medical resource use 495 
costs.35 Firstly, the source data reported resource use across the US migraine population, and the 496 
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resource use among patients who have failed a previous preventive therapy is likely to be greater. 497 
Secondly, the study reported only headache days, only a proportion of which will be migraine days, so 498 
the resource use per migraine day will also be an underestimation. 499 
The model is also limited by several simplifying assumptions, most notably the assumption that patients 500 
remain untreated after discontinuation. Whilst this may not be reflective of clinical practice, the lack of 501 
long-term, sequential treatment data prevents other scenarios from being explored. Finally, it is not 502 
certain that the MMD of patients treated only with acute medication would be constant over time. 503 
Whilst the inclusion of the placebo reduction is essential in assessing the treatment effect of erenumab 504 
in a clinical trial context, its relevance to economic evaluation as a potential comparator is limited. It is 505 
also possible that patients whose migraines are not controlled with preventive therapy, and instead rely 506 
only on acute medication, may experience increased MMD over time, due to pain medication overuse.14 507 
  508 
Conclusion 509 
The VBP ranges presented in this manuscript represent the value of erenumab, as assessed within the 510 
scenarios described under a cost-effectiveness framework. However, cost-effectiveness is just one 511 
criterion against which value can be assessed and affordability and other factors also impact final price. 512 
In this study, erenumab showed consistent and meaningful improvements in migraine day frequency 513 
and QALY compared to SC for patients who have failed at least one prior generic preventive therapy. 514 
The results presented provide the range of prices at which erenumab would be considered a valuable 515 
addition as migraine prevention in people with migraine, based on established WTP thresholds in the 516 
US. The value demonstration framework based on willingness to pay for health gains offers a meaningful 517 
approach to understand product value in relation to potential prices. Our analysis also highlights 518 
potential cost savings that can be achieved for people with migraine attributed to acute migraine day 519 
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treatment costs, physician costs and improved productivity output, suggesting benefits for both health 520 
services and broader societal impact. In the post-launch period, the economic results described here can 521 
be enriched to more accurately define clinical and economic value. 522 
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Supplementary materials 670 
A) Modeling approaches 671 
 672 
Migraine day frequency analysis  673 
The primary endpoints of the clinical studies were the reduction in the mean MMD from baseline. 674 
However, change in mean MMD across a cohort of patients does not capture all clinically meaningful 675 
impacts of migraine preventive therapy.  676 
Modeling the distribution of patients by MMD allows the application of outcomes stratified by the 677 
number of migraine days in each cycle, with outcomes estimated as a function of migraine days 678 
observed. In doing this, the model can account for non-linear relationships between MMD and 679 
associated cost and quality of life outcomes, for example patient utility, where the marginal disutility of 680 
each incremental migraine day increases towards the upper end of the frequency range.  681 
The parametric approach adopted in the model estimates both the change in mean MMD over time and 682 
the distribution of the migraine day counts of individual patients over each 28-day cycle. Discrete 683 
probability distributions are assumed, in which a migraine day ŝƐ ĐŽŶƐŝĚĞƌĞĚ Ă  “ƐƵĐĐĞƐƐ ? ĂŶĚ Ă ŶŽŶ-684 
migraine day ŝƐ ĐŽŶƐŝĚĞƌĞĚ Ă  “ĨĂŝůƵƌĞ ? ? ƐƵƉƉŽƌƚŝŶŐ ƚŚĞ ƌĂŶŐĞ ŽĨ ƉŽƐƐŝďůĞ ŶƵŵďĞƌƐ ŽĨ migraine days 685 
observable within each cycle: a minimum of 0 and a maximum of 28. The distributions of patients in 686 
each cycle are used to estimate the weighted average cost and quality of life outcomes of the cohort, 687 
based on the proportions experiencing each number of migraine days, and the respective outcomes for 688 
each frequency.  689 
The MMD of patients in each health state are estimated via four steps. Firstly, the baseline MMD of the 690 
cohort is derived from the pre-treatment baseline phase of the clinical studies. Secondly, a reference 691 
change in MMD is determined by the reductions in frequency observed in the placebo arms of the 692 
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erenumab clinical studies. Thirdly, the treatment effects of active preventive medication (erenumab and 693 
onabotulinumtoxinA), relative to the placebo reductions, are then applied to estimate the mean MMD 694 
in each model cycle. Finally, the distribution of patients by migraine day frequency is then estimated 695 
using the distribution parameters derived from the patient-level data.  696 
Estimation of placebo change in migraine day frequency 697 
The changes in MMD for placebo (to which the treatment effects of active preventives are applied) are 698 
based on a longitudinal analysis of migraine day count data from patients in the placebo arms of the EM 699 
and CM clinical studies (20120296 and 20120295) who had failed at least one prior preventive therapy 700 
at baseline.24, 45 Longitudinal non-linear, hierarchical regression models were fitted to patient-level 701 
migraine day ĨƌĞƋƵĞŶĐǇĚĂƚĂĨƌŽŵƚŚĞƐĞƉĂƚŝĞŶƚƐŽǀĞƌƚŚĞƐƚƵĚŝĞƐ ?ĚŽƵďůĞ-blind treatment phases. The 702 
response variable (the number of migraine days reported in each 28-day observation period) was 703 
assumed to follow negative binomial or beta-binomial distributions. These distributions have previously 704 
been shown to accurately approximate the distributions of migraine day count data from the erenumab 705 
clinical studies.33, 34 In addition to the mean migraine day counts over 28 days (28 Bernoulli trials), the 706 
negative binomial and beta binomial distributions are characterized by additional parameters which 707 
account for the spread of individuals by migraine day frequency (the dispersion parameter and intra-708 
class correlation coefficient, respectively). The longitudinal regressions provide estimates of these 709 
parameters, which are assumed constant across the patient population, irrespective of treatment and 710 
time. The fits of the negative binomial and beta binomial regression models were compared, and the 711 
negative binomial models are adopted in the base case analyses.  712 
In the EM comparison to SC, patients are assumed to receive no reduction from their baseline frequency 713 
at the start of the clinical studies, and their MMD is assumed constant at their pre-randomization 714 
baseline observation. In the scenario analyses including the placebo effect, the placebo change from 715 
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baseline in MMD from the clinical study is assumed to represent the natural history of migraine over the 716 
course of the model. 717 
 718 
Application of relative treatment effects 719 
The reductions in MMD associated with erenumab and onabotulinumtoxinA are derived from the results 720 
of a NMA of RCT data for migraine preventives.32 The relative effects are applied to the regression 721 
models which were fitted to the placebo arms of the erenumab clinical studies, to generate comparable 722 
estimates of MMD, based on the indirect comparison performed as part of the NMA. 723 
The NMA assessed absolute differences in MMD reductions from baseline in 15 EM clinical studies and 724 
22 CM studies. The results of the NMA are used to derive the additional reductions in MMD for 725 
erenumab and onabotulinumtoxinA in EM and CM, relative to the reductions in the combined placebo 726 
arms. In EM, erenumab 140mg was estimated to reduce MMD by 1.9 (95% CrI: 0.8  W 3.0) compared to 727 
placebo. In CM, the estimated reductions versus placebo were 2.3 (95% CrI: -1.0  W 5.6) and 2.2 (95% CrI: 728 
0.6 - 4.3) for erenumab and onabotulinumtoxinA, respectively.  729 
Although there was some variation in the duration of the double-blind phases of the studies (EM: 12-26 730 
weeks, CM: 12-24 weeks), the estimates of relative reductions in MMD are applied at the end of the 731 
erenumab studies (EM: 24 weeks, CM: 12 weeks). When applying the relative effects in the model, the 732 
additional reduction of active prevention is applied gradually over time, proportional to the reduction 733 
estimated in the placebo longitudinal regression models, such that at the start of the model the 734 
treatment effect is 0%, and at the time point equal to the end of the relevant double-blind phase (EM: 735 
24 weeks, CM: 12 weeks) the treatment effect is 100% (i.e. the full relative reduction is applied). 736 
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As the NMA assessed MMD reductions in published clinical studies, the results reflect the mix of 737 
treatment naïve and treatment experienced patients enrolled in each, and not the prior failure subgroup 738 
that is the subject of this evaluation. To account for this in the model, the absolute changes from 739 
baseline for erenumab and onabotulinumtoxinA in patients who have failed prior therapy are assumed 740 
to be equal to those observed in the full clinical study group. This assumption is supported by the fact 741 
that the absolute changes from baseline for erenumab in the pivotal EM and CM studies were consistent 742 
across patient subgroups based on the number of failed prior preventive treatments.25 743 
Finally, the mean MMD predicted by the longitudinal regression models are extrapolated up to a 744 
maximum of 2 years. The extrapolations are performed assuming a logistic function, the best fitting of 745 
four parametric functions tested for goodness of fit (exponential, logistic, log-logistic and Gompertz). 746 
Although the reductions for all comparators were extrapolated up to 2 years, migraine day frequency 747 
plateaued quickly and was constant from around 6 months. 748 
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Figure 4: Modeled migraine day frequency per 28 days over first year of the model, EM and CM 749 
ƉĂƚŝĞŶƚƐƵďŐƌŽƵƉƐǁŝƚŚш ?ƉƌŝŽƌƚƌĞĂƚŵĞŶƚĨĂŝůƵƌĞĂƚďĂƐĞůŝŶĞ 750 
 751 
EM, episodic migraine; CM, chronic migraine 752 
Discontinuation 753 
OnabotulinumtoxinA discontinuation rates applied in the model are derived from real world persistence 754 
data from 2017 US prescription claims data.38 An exponential distribution was fitted to the proportion of 755 
patients remaining persistent on onabotulinumtoxinA over 1 year, and this was used to derive the 756 
transition probabilities of onabotulinumtoxinA ƉĂƚŝĞŶƚƐďĞƚǁĞĞŶƚŚĞ  “ŽŶƉƌĞǀĞŶƚŝǀĞ ƚŚĞƌĂƉǇ ? ĂŶĚ  “ŽĨĨ 757 
preventive ƚŚĞƌĂƉǇ ?ŚĞĂůƚŚƐƚĂƚĞƐ ? 758 
No data is currently available on real-world persistency with erenumab. However, data were available 759 
from an NMA of migraine clinical trial data on the comparative rates of all-cause discontinuation. To 760 
account for differences in the duration of included studies, discontinuation was converted to a rate of 761 
discontinuation per 4 weeks, assuming a constant rate over the reported trial duration. The NMA 762 
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included data from 22 EM studies and 9 CM studies, and reported a median rate ratio (RR) of 763 
discontinuation every 4 weeks for erenumab compared to onabotulinumtoxinA of 0.40 (95% CI: 0.11  W 764 
1.75). This RR was applied to the exponential discontinuation curve fit to the onabotulinumtoxinA data 765 
to estimate the expected real-world persistence of patients treated with erenumab (Figure 5).  766 
In the base case analysis, patients in the SC arm are not receiving preventive therapy and therefore do 767 
not discontinue. Once patients with erenumab or onabotulinumtoxinA discontinue, they transition to 768 
ƚŚĞ  “ŽĨĨƉƌĞǀĞŶƚŝǀĞ ƚŚĞƌĂƉǇ ?ŚĞĂůƚŚ ƐƚĂƚĞĂŶĚĂƌĞĂƐƐƵŵĞĚ ƚŽĞǆƉĞƌŝĞŶĐĞ ƚŚĞ migraine day frequency 769 
equal to that of SC (i.e. the incremental treatment effect is lost instantaneously), and patients return to 770 
their pre-treatment migraine days baseline. It is assumed that discontinued patients receive no further 771 
preventive therapy. This assumption is required in the absence of clinical study data on the sequential 772 
use of preventive treatments. 773 
In the scenario analyses in which untreated patients are assumed to receive the placebo effect from the 774 
clinical studies, patients are assumed to also experience the placebo reduction post-discontinuation, 775 
rather than returning to their baseline frequency.  776 
 777 
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Figure 5: Estimation of erenumab and onabotulinumtoxinA discontinuation rates 778 
 779 
NMA, network meta-analysis; RR, rate ratio 780 
 781 
Mortality 782 
General population mortality in the model is based on US life tables.31 Annual risks of death reported are 783 
converted to a per-cycle risk of death and inform the transitions to the death health state. Treatment 784 
effects and migraine frequency do not affect the risks of death in the model, as migraine is not 785 
associated with an increased mortality risk. 786 
 787 
  788 
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B) Outcomes applied by migraine day frequency per 28 days 789 
Table 5: Outcomes applied by migraine day frequency per 28 days, summary table 790 
Migraine 
days 
Mean resource use Migraine 
Specific Acute 
med days 
Non-migraine 
Specific Acute 
med days 
Absenteeism 
days 
Presenteeism 
days 
Utility - On treatment 
(Erenumab/ 
OnabotulinumtoxinA) 
Utility - Off 
treatment 
Physician 
visits 
Emergency 
room visits 
Hospital 
stay 
Specialist 
consultation 
0 0.000 0.000 0.000 0.000 1.474 1.833 0.633 1.259 0.823 0.812 
1 0.038 0.009 0.004 0.012 1.611 1.931 0.668 1.358 0.811 0.799 
2 0.076 0.018 0.008 0.023 1.759 2.034 0.704 1.466 0.799 0.786 
3 0.114 0.026 0.012 0.035 1.922 2.143 0.743 1.582 0.786 0.773 
4 0.152 0.035 0.016 0.047 2.099 2.258 0.783 1.707 0.773 0.759 
5 0.189 0.044 0.020 0.058 2.293 2.378 0.826 1.841 0.758 0.744 
6 0.227 0.053 0.024 0.070 2.504 2.505 0.871 1.987 0.744 0.729 
7 0.265 0.062 0.028 0.081 2.736 2.639 0.919 2.144 0.729 0.713 
8 0.303 0.070 0.032 0.093 2.988 2.780 0.969 2.313 0.713 0.697 
9 0.341 0.079 0.036 0.105 3.264 2.928 1.021 2.496 0.696 0.680 
10 0.379 0.088 0.039 0.116 3.565 3.084 1.077 2.693 0.680 0.663 
11 0.417 0.097 0.043 0.128 3.894 3.249 1.136 2.906 0.662 0.645 
12 0.455 0.105 0.047 0.140 4.254 3.423 1.198 3.136 0.645 0.627 
13 0.493 0.114 0.051 0.151 4.646 3.605 1.263 3.384 0.626 0.608 
14 0.531 0.123 0.055 0.163 5.075 3.798 1.332 3.651 0.608 0.590 
15 0.568 0.132 0.059 0.174 5.544 4.001 1.405 3.939 0.589 0.571 
16 0.606 0.141 0.063 0.186 6.056 4.214 1.481 4.251 0.570 0.551 
17 0.644 0.149 0.067 0.198 6.615 4.439 1.562 4.586 0.551 0.532 
18 0.682 0.158 0.071 0.209 7.225 4.676 1.647 4.949 0.531 0.512 
19 0.720 0.167 0.075 0.221 7.892 4.926 1.737 5.340 0.512 0.493 
20 0.758 0.176 0.079 0.233 8.621 5.189 1.832 5.762 0.492 0.473 
21 0.796 0.185 0.083 0.244 9.416 5.466 1.932 6.217 0.472 0.454 
22 0.834 0.193 0.087 0.256 10.286 5.758 2.037 6.708 0.453 0.434 
23 0.872 0.202 0.091 0.268 11.235 6.065 2.148 7.238 0.433 0.415 
24 0.909 0.211 0.095 0.279 12.272 6.389 2.265 7.810 0.414 0.396 
25 0.947 0.220 0.099 0.291 13.405 6.730 2.389 8.427 0.395 0.378 
26 0.985 0.229 0.103 0.302 14.642 7.090 2.519 9.093 0.377 0.359 
27 1.023 0.237 0.107 0.314 15.994 7.468 2.656 9.811 0.359 0.341 
28 1.061 0.246 0.111 0.326 17.470 7.867 2.801 10.587 0.341 0.324 
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C) Scenario analysis results 791 
Scenario analysis 1: comparison including placebo effect 792 
Table 6: Scenario analysis: inclusion of placebo effect 793 
Comparison Erenumab SC Incremental 
Migraine days  1,554 1,632 -78 
QALYs 5.3612 5.2407 0.1205 
Migraine day-
related costs* 
$108,877 $113,654 -$4,777 
Value based price $8,886 - $15,250 - - 
*Cost estimates do not include the costs of providing preventive medication, as a price of erenumab is not 794 
available 795 
 796 
Scenario analysis 2: comparison including placebo effect and excluding indirect costs 797 
Table 7: Scenario analysis: inclusion of placebo effect and exclusion of indirect costs 798 
Comparison Erenumab SC Incremental 
Migraine days  1,554 1,632 -78 
QALYs 5.3612 5.2407 0.1205 
Migraine day-
related costs* 
$40,241 $42,289 -$2,048 
Value based price $7,445 - $13,809 - - 
*Cost estimates do not include the costs of providing preventive medication, as a price of erenumab is not 799 
available 800 
 801 
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Scenario analysis 3: Assuming 50% patients EM and 50% patients CM 802 
Table 8: Scenario analysis: Assuming 50% patients EM and 50% patients CM 803 
Comparison Erenumab SC Incremental 
Migraine days  1,606 1,739 -133 
QALYs 5.3474 5.1728 0.1747 
Migraine day-related costs* $110,478 $118,261 -$7,783 
Value based price $13,331 - $22,553 - - 
*Cost estimates do not include the costs of providing preventive medication, as a price of erenumab is not 804 
available 805 
 806 
Scenario analysis 4: Comparison of erenumab to onabotulinumtoxinA in 100% CM patients  807 
Table 9: Scenario analysis: Comparison of erenumab to onabotulinumtoxinA in 100% CM patients  808 
Comparison Erenumab OnabotulinumtoxinA Incremental 
Migraine days  2,200 2,301 -101 
QALYs 4.7374 4.6155 0.1219 
Migraine day-related costs* $143,198 $149,084 -$5,886 
Value based price $12,151 - $18,589 - - 
 809 
*Cost estimates do not include the costs of providing preventive medication, as a price of erenumab is not 810 
available 811 
 812 
 813 
